Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigen-specific TCR and its humanized derviative is governed by the CD8 coreceptor and affects natural human TCR expression

Immunologic Research

Volumn 34, Issue 1, 2006, Pages 67-87

  Voss, Ralf Holger ^a   Kuball, Jürgen ^a,d   Engel, Renate ^a   Guillaume, Philippe ^b   Romero, Pedro ^c   Huber, Christoph ^a   Theobald, Matthias ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

^c Hopital Orthopedique de la Suisse Romande   (Switzerland)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

CD8 ; MDM2; T cell; T cell antigen receptor; Tumor immunity

Indexed keywords

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; EPITOPES, T-LYMPHOCYTE; FLOW CYTOMETRY; HLA-A2 ANTIGEN; HUMANS; MICE; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEINS C-MDM2; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SELF TOLERANCE;

EID: 33646889967     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/IR:34:1:67     Document Type: Article

References (55)

1. Melief CJ, Toes RE, Medema JP, van der Burg SH, Ossendorp F, Offringa R: Strategies for immunotherapy of cancer. Adv Immunol 2000;75:235-282.
2. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992;358:80-83.
3. Roth J, Dobbelstein M, Freedman DA, Shenk T, Levine AJ: Nucleo-cytoplasmatic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J 1998;17:554-564.
4. Freedman DA, Levine AJ: Regulation of the p53 protein by the MDM2 oncoprotein - thirty-eighth G.H.A. Clowes memorial award lecture. Cancer Res 1999;59:1-7.
5. Stanislawski T, Voss RH, Lotz C, et al: Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol 2001;2:962-970.
6. Trotta R, Vignudelli T, Candini O, et al: BCR/ABL activates mdm2 mRNA translation via the La antigen. Cancer Cell 2003;3:145-160.
7. Theobald M, Biggs J, Hernandez J, Lustgarten J, Labadie C, Sherman LA: Tolerance to p53 by A2.1-restricted T lymphocytes. J Exp Med 1997;185:833-841.
8. Vierboom MP, Nijman HW, Offringa R, et al: Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J Exp Med 1997;186:695-704.
9. Kuball J, Schuler M, Antunes Ferreira E, et al: Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man. Gene Ther 2002;9:833-843.
10. Lotz C, Ferreira EA, Drexler I, et al: Partial tyrosinase-specific self tolerance by HLA-A*0201-restricted cytotoxic T lymphocytes in mice and man. Int J Cancer 2004;108:571-579.
11. Zeh HJ, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC: High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 1999;162:989-994.
12. Yang S, Linette GP, Longerich S, Haluska FG: Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity. J Immunol 2002;169:531-539.
13. Gronsky MA, Boulter JM, Moskophidis D, et al: TCR affinity and negative regulation limit autommunity. Nat Med 2004;10:1234-1239.
14. Sherman LA, Hesse SV, Irwin MJ, La Face D, Peterson P: Selecting T cell receptors with high affinity for self-MHC by decreasing the contribution of CD8. Science 1992;258:815-818.
15. Pittet MJ, Rubio-Godoy V, Bioley G, et al: α3 domain mutants of peptide/MHC class I multimers allow the selective isolation of high avidity tumor-reactive CD8 T cells. J Immunol 2003;171:1844-1849.
16. Romero P, Dunbar PR, Valmori D, et al: Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytoloytic T lymphocytes. J Exp Med 1998;188:1641-1650.
17. Voss R-H, Kuball J, Theobald M: Designing TCR for cancer immunotherapy; in: Ludewig B, Hoffmann MW (eds): Adoptive Immunotherapy: Methods and Protocols. Totowa, NJ, Humana, 2004, pp.229-256.
18. + T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity 2005;22:117-129.
19. Campanelli R, Palermo B, Garbelli S, et al: Human CD8 co-receptor is strictly involved in MHC-peptide tetramer-TCR binding and T cell activation. Int Immunol 2002;14:39-44.
20. Wooldridge L, Hutchinson SL, Choi EM, et al: Anti-CD8 antibodies can inhibit or enhance peptide-MHC class I (pMHCI) multimer binding: This is paralleled by their effects on CTL activation and occurs in the absence of an interaction between pMHCI and CD8 on the cell surface. J Immunol 2003;171:6650-6660.
21. Devine L, Hudson ME, Daniels MA, Jameson SC, Kavathas PB: Location of the epitope for an anti-CD8α antibody 53.6.7 which enhances CD8α-MHC class I interaction indicates antibody stabilization of a higher affinity CD8 conformation. Immunol Lett 2004;93:123-130.
22. Garcia KC, Degano M, Stanfield RL, et al: An αβ T cell receptor structure at 2.5 Å and its orientation in the TCR-MHC complex. Science 1996;274:209-219.
23. Holman PO, Walsh ER, Jameson SC: Characterizing the impact of CD8 antibodies on class I MHC multimer binding. J Immunol 2005;174:3986-3991.
24. Witte T, Spoerl R, Chang HC: The CD8β ectodomain contributes to the augmented coreceptor function of CD8αβ heterodimers relative to CD8αα homodimers. Cell Immunol 1999;191:90-96.
25. Nascimbeni M, Shin EC, Chiriboga L, Kleiner DE, Rehermann B: Peripheral CD4+CD8+ T cells are differentiated effector memory cells with antiviral functions. Blood 2004;104:478-486.
26. Gangadharan D, Cheroutre H: The CD8 isform CD8αα is not a functional homologue of the TCR co-receptor CD8αβ. Curr Opin Immunol 2004;16:264-270.
27. Grossman WJ, Verbsky JW, Tollefsen BL, Kemper C, Atkinson JP, Ley TJ: Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood 2004;104:2840-2848.
28. Lanzavecchia A, Sallusto F: Progressive differentiation and selection of the fittest in the immune response. Nat Rev Immunol 2002;2:982-987.
29. Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA, Nishimura MI: Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol 1999;163:507-513.
30. Kessels HW, Wolkers MC, van den Boom M.D, van der Valk MA, Schumacher TN: Immunotherapy through TCR gene transfer. Nat Immunol 2001;2:957-961.
31. Heemskerk MH, Hoogeboom M, de Paus RA, et al: Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. Blood 2003;102:3530-3540.
32. Heemskerk MH, Hoogeboom M, Hagedoorn R, Kester MG, Willemze R, Falkenburg JH: Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. J Exp Med 2004;199:885-894.
33. Chamoto K, Tsuji T, Funamoto H, et al: Potentiation of tumor eradication by adoptive immunotherapy with T-cell receptor gene-transduced T-helper type 1 cells. Cancer Res 2004;64:386-390.
34. Itano A, Salmon P, Kioussis D, Tolaini M, Corbella P, Robey E: The cytoplasmic domain of CD4 promotes the development of CD4 lineage T cells. J Exp Med 1996;183:731-741.
35. + T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR αβ gene transfer requires CD8α. Gene Ther 2005;12:140-146.
36. Morris EC, Tsallios A, Bendle GM, Xue SA, Stauss HJ: A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection. Proc Natl Acad Sci USA 2005;102:7934-7939.
37. Roszkowski JJ, Yu DC, Rubinstein MP, McKee MD, Cole DJ, Nishimura MI: CD8-independent tumor cell recognition is a property of the T cell receptor and not the T cell. J Immunol 2003;170:2582-2589.
38. Morgan RA, Dudley ME, Yu YY, et al: High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J Immunol 2003;171:3287-3295.
39. + melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor. Cancer Res 2005;65:1570-1576.
40. Zhao Y, Zheng Z, Robbins PF, Khong HT, Rosenberg SA, Morgan RA: Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J Immunol 2005;174:4415-4423.
41. Holler PD, Chlewicki LK, Kranz DM: TCRs with high affinity for foreign pMHC show self-reactivity. Nat Immunol 2003;4:55-62.
42. Kessels HW, van den Boom MD, Sprits H, Hooijberg E, Schumacher TN: Changing T cell specificity by retroviral T cell receptor display. Proc Natl Acad Sci USA 2000;97:14578-14583.
43. + T cells: it may get by with a little help from its friends. J Clin Invest 2002;110:1415-1417.
44. + T lymphocytes. Nature 2003;421:852-856.
45. + T cells after acute infection. Nat Immunol 2004;5:927-933.
46. Wherry EJ, Teichgraber V, Becker TC, et al: Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 2003;4:225-234.
47. Bendle GM, Holler A, Pang LK, et al: Induction of unresponsiveness limits tumor protection by adoptively transferred MDM2-specific cytotoxic T lymphocytes. Cancer Res 2004;64:8052-8056.
48. Stumbles PA, Himbeck R, Frelinger JA, Collins EJ, Lake RA, Robinson BW: Cutting edge: Tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation. J Immunol 2004;173:5923-5928.
49. Breedveld FC: Therapeutic monoclonal antibodies. Lancet 2000;355:735-740.
50. Berger C, Huang ML, Gough M, Greenberg PD, Riddell SR, Kiem HP: Nonmyeloablative immunosuppressive regimen prolongs in vivo persistence of gene-modified autologous T cells in a nonhuman primate model. J Virol 2001;75:799-808.
51. Berger C, Blau CA, Huang ML, et al: Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model. Blood 2004;103:1261-1269.
52. Luznik L, Jalla S, Engstrom LW, lannone R, Fuchs EJ: Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood 2001;98:3456-3464.
53. Ruggeri L, Capanni M, Urbani E, et al: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295:2097-2100.
54. Dudley ME, Wunderlich JR, Robbins PF, et al: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-854.
55. Call ME, Pyrdol J, Wiedmann M, Wucherpfenning KW: The organizing principle in the formation of the T cell receptor-CD3 complex. Cell 2002;111:67-979.